Always Remember - Buy The Dip

Sentiment Analysis For AKRX

The news is currently generally neutral for AKRX.

Based on TextBlob analysis of Yahoo! Finance news summaries for AKRX on 2015-09-09.

Yahoo! Finance News for AKRX

October 16th Options Now Available For Akorn (AKRX)
Investors in Akorn Inc (Symbol AKRX) saw new options begin trading today, for the October 16th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the AKRX options chain for the new October 16th

Notable Two Hundred Day Moving Average Cross - AKRX
In trading on Thursday, shares of Akorn Inc (Symbol AKRX) crossed below their 200 day moving average of $43.94, changing hands as low as $42.81 per share. Akorn Inc shares are currently trading off about 4.7% on the day.

A Pharma ETF Focused On Quality, Fast-Growing Stocks
D rugmakers delivered tasty returns to investors in July. Pharmaceutical ETFs topped peers holding broadly diversified health care stocks as well as those focused on red hot biotechs. PowerShares Dynamic Pharmaceuticals ( PJP ) lags its

AKRX''s NASDAQ Compliance Plan Accepted, Cellceutix, Viveve Make Big Moves
AKRX''s NASDAQ Compliance Plan Accepted, Cellceutix, Viveve Make Big Moves

Commit To Buy Akorn At $40, Earn 15.6% Annualized Using Options
Investors considering a purchase of Akorn Inc (Symbol AKRX) stock, but cautious about paying the going market price of $44.10 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in

Inspire Pharmaceuticals Settles Federal Fraud Claims
Inspire Pharmaceuticals Settles Federal Fraud Claims

Akorn (AKRX) Shares Cross Below 200 DMA
In trading on Tuesday, shares of Akorn Inc (Symbol AKRX) crossed below their 200 day moving average of $41.33, changing hands as low as $40.33 per share. Akorn Inc shares are currently trading off about 3.8% on the day.

Monday Sector Laggards: Biotechnology, Drugs
In trading on Monday, biotechnology shares were relative laggards, down on the day by about 1.5%. Helping drag down the group were shares of Celladon Corporation ( CLDN ), off about 79.2% and shares of Capricor Therapeutics ( CAPR

3 Best Stocks for Investing in Generic Drugs
Source FoolEditorial on Flickr. Americans spent more on prescription drugs last year than ever before nearly $374 billion, according to IMS Health . That figure reflected a 13.1%

Can The Uptrend Continue for Akorn (AKRX)? - Tale of the Tape
Investors certainly have to be happy with Akorn, Inc. ( AKRX ) and its short term performance. After all, the stock has jumped by 21.6% in the past 4 weeks, and it is also above its 20 Day Simple

Actavis and Rhythm Start Mid-Stage Study on Relamorelin - Analyst Blog
ActavisACT and biopharmaceutical company, Rhythm, announced the initiation of a phase IIb study on relamorelin. The study is assessing the efficacy and safety of relamorelin (10 mcg to 100 mcg) over three months for the treatment of gastroparesis in

Teva, Xenon Start Phase II Postherpetic Neuralgia Study - Analyst Blog
Teva Pharmaceutical Industries LimitedTEVA and Xenon Pharmaceuticals Inc. XENE announced the enrolment of the first patient in a phase IIb study on their pain management candidate, TV 45070 (4% and 8% w w ointment). The candidate is being developed

Actavis in Patent Infringement Lawsuit for Gilead's Letairis - Analyst Blog
Actavis plcACT confirmed that it is seeking FDA approval for its generic version of Gilead Sciences, Inc.'s GILD Letairis (5 mg and 10 mg). Letairis is approved for the treatment of pulmonary arterial hypertension. Gilead and Royalty Pharma Collection

Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 5.5% - Tale of the Tape
Supernus Pharmaceuticals, Inc. ( SUPN ) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in

3 Reasons Why Akorn (AKRX) Is a Great Growth Stock - Tale of the Tape
Finding a great growth stock can be a tough task. Not only are there a wide range of choices, but the space can be extremely volatile and fraught with risk as well. But thanks to our new style score

Mallinckrodt Reports Acthar Gel Data on Nephrotic Syndrome - Analyst Blog
Mallinckrodt plcMNK reported two separate presentations by independent physicians on patients treated with H.P. Acthar Gel. The presentations showed that Achtar led to positive outcomes in the remission of proteinuria, or excess protein in the urine, caused by nephrotic

Health Care Sector Update for 03/20/2015: PRTO, AKRX, ICPT
Top health care stocks JNJ flat PFE +0.1% ABT flat MRK +0.5 AMGN +0.8% Health care shares were generally higher in pre market trading Friday. Proteon Therapeutics ( PRTO ), a biopharmaceutical company, reported Friday a narrower net loss